Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-17
    E.g., 2018-11-17

Articles

173760 items
7:55 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Roivant, now valued at $7B, raises $200M in equity financing

Roivant Sciences GmbH (Basel, Switzerland) raised $200 million in its fourth equity financing on Nov. 13, which Roivant says values the company at about $7 billion. New investors NovaQuest Capital Management and RTW Investments joined...
7:54 AM, Nov 16, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics Inc. (Cambridge, Mass.) closed an untranched $65 million series B round on Nov. 13 to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to...
7:54 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

U.K. Parliament issues ultimatum to Vertex, NHS, NICE

In a last ditch effort to bring to a close a years-long fight over access to cystic fibrosis drugs in the U.K., a Parliament committee said it would release on Nov. 30 documents it has...
7:53 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Other News

CFIUS pilot launch marks steps into biotech territory

Biotech could soon be getting more attention from the Committee of Foreign Investment in the United States as the Treasury Department's CFIUS pilot program went into effect over the weekend. "Biotech is still relatively new to...
7:53 AM, Nov 16, 2018  |  BC Week In Review | Clinical News  |  Preclinical Results

Fecal transplant could treat toxicity common to checkpoint inhibitors

University of Texas MD Anderson Cancer Center researchers used fecal transplants to treat refractory immune checkpoint inhibitor-associated colitis in cancer patients. Colitis is one of the most common toxicities associated with checkpoint inhibitor immunotherapy, occurring in...
7:53 AM, Nov 16, 2018  |  BC Week In Review | Clinical News  |  Preclinical Results

Seal Rock's ASK1 inhibitor improves NASH symptoms in mice

Seal Rock Therapeutics Inc. (Seattle, Wash.) said lead candidate SRT-015 significantly improved metabolic parameters and liver-specific pathology in a mouse model of non-alcoholic steatohepatitis (NASH). The liver-selective apoptosis signal-regulating kinase 1 (ASK1; MAP3K5) inhibitor also...
7:52 AM, Nov 16, 2018  |  BC Week In Review | Clinical News  |  Regulatory

Theravance secures U.S. approval for Yupelri in COPD

Theravance Biopharma Inc. (NASDAQ:TBPH) and partner Mylan N.V. (NASDAQ:MYL) said FDA approved Yupelri revefenacin as a maintenance treatment of chronic obstructive pulmonary disease. Yupelri marks the first once-daily nebulized bronchodilator to receive U.S. approval for...
1:16 PM, Nov 09, 2018  |  BC Week In Review | Company News  |  Deals

Cue, LG in biologics deal

Cue Biopharma Inc. (NASDAQ:CUE) granted LG Chem Life Sciences exclusive development and commercialization rights in certain Asian-Pacific countries, including Japan, China and Korea, and Australia to CUE-101 and Cue's Immuno-STAT biologics that target T cells...
1:04 PM, Nov 09, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA approves direct-to-consumer test, warns against others

After authorizing a genetic test from 23andMe Inc. (Mountain View, Calif.), FDA issued a warning against using unapproved tests to guide medical decisions. On Oct. 31, FDA said the Personal Genome Service Pharmacogenetic Reports test from...
1:02 PM, Nov 09, 2018  |  BC Week In Review | Company News  |  Other News

NIH's BRAIN Initiative adds $220M in new awards

NIH said its Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative will fund more than 200 new awards totalling over $220 million. The awards will go to researchers investigating new tools and techniques to image...

Pages